Earnings tipped to multiply by three

Two companies are looking to almost triple their earnings by the end of this decade and our readers wanted to know who - and how - in our top read story this week.

With the obesity juggernaut showing no sign of slowing down, it's perhaps not surprising that Novo Nordisk and Eli Lilly are expected to top the earnings list, according to analysts at Evaluate. It's described as quite the "turn of the tables" given neither company had even made the Top 10 until last year.

Novo which brought in more than US$30 billion in drug sales last year is expected to hit a breathtaking US$90 billion by 2030 with three blockbuster drugs - Ozempic, Wegovy and the yet-to-be approved CagriSema. Lilly will be a smidgen behind, with Mounjaro and Zepbound heavily contributing to that figure. Find out who else will be doing well in: Whose revenue is about to triple?